1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 18th March 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Mitochondrial protein interaction landscape of SS-31, 2020, Chavez et al.

Discussion in 'Other health news and research' started by Jaybee00, Jun 19, 2020.

  1. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    1,857
    https://www.pnas.org/content/early/2020/06/16/2002250117

    popular article here https://newsroom.uw.edu/news/study-yields-clues-how-drug-may-boost-aged-mitochondria

     
  2. Ravn

    Ravn Senior Member (Voting Rights)

    Messages:
    2,042
    Location:
    Aotearoa New Zealand
    Much too technical for my understanding but there do seem to be a few interesting points here (IIRC SS31 was the molecule that had the best effect in the "something in the blood" nano-needle tests).
    • SS31 has no effect on mitochondrial function in young, healthy mitochondria, only on old or sick ones - hmm, what does that imply about our mitos?
    • SS31 improves function of complex V - the very complex which may not be working efficiently in ME.
    • SS31 may affect 2-OG signalling, 2-OG being thought a sort of master regulator metabolite affecting ATP synthase and target of rapamycin (TOR) and also being involved in hypoxia signalling - all stuff that keeps turning up in ME studies.
    • SS31 interacts with cardiolipin - antibodies against cardiolipin have been found in ME.
    I've no idea of the true relevance of any of this.
     

Share This Page